The seller's regulatory history is now part of what the buyer is actually buying.
Veron P. Browne, PhD, Co-founder, Alenvo · 3 min read
Published
Biopharma deal activity in 2026 is on pace for a record year, with approximately $199 billion across M&A and licensing by late August, according to BioWorld. Record years tend to compress diligence. They also tend to reveal where diligence falls short.
The transparency era has done something quietly significant for the buyers in those deals.
For most of the last two decades, a diligence team evaluating a drug asset had to work from what the seller chose to share, what the public clinical trial record contained, and whatever investigator or review-division contacts the team could reach. The seller's prior Complete Response Letters, if any, were not public. The specific concerns a review division had raised in adjacent programs were not systematically available. A diligence memo was always, in part, a document about what the diligence team didn't know.
That ground has shifted. The FDA CRL database, roughly 458 records by mid-2026, is now a searchable corpus of what review divisions have actually refused. Advisory committee materials and briefing packages have been public for longer. Together, they let a buyer evaluate the seller's regulatory record and the review division's documented pattern in a way that was not possible at scale eighteen months ago.
Consider the Biohaven and SK Biopharmaceuticals licensing transaction. On August 26, 2026, Biohaven licensed global rights to opakalim, its Kv7.2/7.3 potassium channel activator in Phase 2/3 development for refractory focal epilepsy, to SK Biopharmaceuticals, with approximately $350 million at closing and up to $795 million in total deal value. Nine days later, on September 4, FDA placed a partial clinical hold on the program, citing a metabolite observed in rodent studies that had not been sufficiently characterized. Biohaven's own regulatory filing confirmed that all clinical and nonclinical data had been disclosed to SK before the deal was signed. The metabolite was in the data room. The question the review division would raise was answerable in advance.
That is not a failure of diligence effort. It is a signal of how much the diligence standard has moved.
The pathway risk a buyer is taking is no longer invisible. It just requires reading the record.
Alenvo Drug Asset Due Diligence is built to make these questions answerable before signing, not after. See our case studies for examples.
This article is general information on public regulatory requirements. It is not regulatory or legal advice, and Alenvo is not affiliated with FDA. Read our editorial standards.
See how Alenvo helps diligence teams read a data room and regulatory record before signing.
Buyers grade the evidence they are handed. The evidence that moves a valuation is usually the evidence that was never in the room.
Perspectives on how development and regulatory decisions actually get made.
In-depth research and regulatory strategy briefs.
Real-world outcomes and customer success stories.
What FDA evaluates in the 30-day review, and what can stop an IND.
Refuse-to-file risk, the filing review, and first-cycle approval risk.